BID #11072
Pharmaceutical Goods and Services
Fluoxetine, Fluphenazine, Topotecan Inj, Cimetidine, and Labetalol
Due Date: Ongoing
PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) VA797P-12-R-0019 for an unrestrictive procurement for Fluoxetine, Fluphenazine, Topotecan Inj, Cimetidine, and Labetalol for the Department of Veterans Affairs (VA), Department of Defense (DOD), Indian Health Service (IHS), and Bureau of Prisons (BOP). The following strengths for each drug are included and estimated annual usage is available upon e-mail request: Fluoxetine 10MG and 20MG; Fluphenazine 1MG, 2.5MG, 5MG, and 10MG; Topotecan HCL 4MG VIL/INJ; Cimetidine 300MG, 400MG, and 800MG; and Labetalol HCL 100MG, 200MG and 300MG. The VA will award one contract per drug to the responsible offerors who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA and DOD"s Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have a unique NDC number. Solicitation # VA797P-12-R-0019 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about June 21, 2012, with a tentative closing date of July 12, 2012. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: http://www.fedbizopps.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Teresa Hussain. Questions can be e-mailed to: [email protected].